1. Home
  2. NEGG vs MDWD Comparison

NEGG vs MDWD Comparison

Compare NEGG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newegg Commerce Inc.

NEGG

Newegg Commerce Inc.

HOLD

Current Price

$55.77

Market Cap

1.6B

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

N/A

Current Price

$18.72

Market Cap

238.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEGG
MDWD
Founded
2001
2000
Country
United States
Israel
Employees
N/A
111
Industry
Other Specialty Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
238.5M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
NEGG
MDWD
Price
$55.77
$18.72
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
162.7K
97.7K
Earning Date
12-01-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,313,127,000.00
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.15
52 Week Low
$3.32
$14.14
52 Week High
$137.84
$22.51

Technical Indicators

Market Signals
Indicator
NEGG
MDWD
Relative Strength Index (RSI) 38.29 55.40
Support Level $52.61 $18.55
Resistance Level $79.60 $19.40
Average True Range (ATR) 5.72 0.61
MACD -2.25 0.08
Stochastic Oscillator 11.75 66.40

Price Performance

Historical Comparison
NEGG
MDWD

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: